SPONSOR
argenx
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 1, Phase 2, Phase 3
Conditions studied: Primary Immune Thrombocytopenia (ITP)Congenital Myasthenic SyndromeCMSMyasthenia GravisMGgMGGeneralized Myasthenia GravisGeneralized Myasthenia Gravis (gMG)AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT06544499 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia (ITP)
NCT06436742 Phase 1
Recruiting
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
Congenital Myasthenic Syndrome
NCT07294170
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia Gravis
NCT04833894 Phase 2, Phase 3
Recruiting
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis